



Imugene Signs Swiss Drug Manufacturer to Speed Her-Vaxx Development

Melbourne, 15 September 2014: Australian biopharmaceutical company Imugene Limited (ASX:IMU) has progressed the manufacture of its proprietary therapeutic HER-2+ cancer immunotherapy HER-Vaxx with the signing of a new contract with peptide company Bachem AG.

Bachem is a specialist in synthesising clinical grade peptides for inclusion and assembly into an immunotherapy delivery platform as needed for the manufacture of HER-Vaxx.

Bachem successfully completed a feasibility study earlier this year of the HER-Vaxx peptide (combining three individual peptide B-cell epitope antigens) and is now developing and validating analytical test methods used in the manufacture of clinical (GMP) grade HER-Vaxx, to be manufactured by Mymetics. The data generated is important content in the Investigator Brochure that will be part of Imugene's FDA IND submission.

HER-Vaxx is a therapeutic gastric & breast cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu, the same biomarker targeted by the US\$6.9 billion per annum drug Herceptin®. HER-Vaxx successfully completed a Phase 1 study in breast cancer and the next stage of development will be a Phase 1b/2 gastric cancer study.

Gastric or stomach cancer is the second most common cause of cancer-related death in the world and the fourth most commonly diagnosed cancer with over 1 million new cases diagnosed each year.

Contact :

Charles Walker
Chief Executive Officer
+61 450 446 990
cwalker[at]imugene.com

Paul A Hopper
Executive Chairman
+1 858 334 5820 (US)
+61 406 671 515 (Australia)
receptogen[at]earthlink.net

Media contact:

Rudi Michelson
Monsoon Communications
+61 3 9620 3333
rudim[at]monsoon.com.au

About Imugene: Imugene (ASX; IMU) is an immuno-oncology biopharmaceutical company developing HER2 +ve gastric and breast cancer immunotherapies. The Company's lead product is HER-Vaxx, a proprietary HER2 +ve cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer. Imugene's corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria. For more information on Imugene, please visit www.imugene.com